Among highly selected patients with stage IIIB non-small cell lung cancer (NSCLC), surgical resection appears to improve overall survival when used as a part of multimodality therapy. NSCLC patients who underwent definitive chemoradiation had an average overall survival of 16.3 months, compared with an average of 25.9 months for those who underwent chemotherapy, radiation, and surgical intervention in any sequence.
Source: Annals of Thoracic Surgery, June 2015.
